nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—ORM1—Abiraterone—prostate cancer	0.148	0.289	CbGbCtD
Maprotiline—CYP1A2—Flutamide—prostate cancer	0.0373	0.0728	CbGbCtD
Maprotiline—CYP2D6—Bicalutamide—prostate cancer	0.0371	0.0724	CbGbCtD
Maprotiline—ABCB1—Estramustine—prostate cancer	0.0366	0.0715	CbGbCtD
Maprotiline—CYP2D6—Abiraterone—prostate cancer	0.0307	0.06	CbGbCtD
Maprotiline—CYP1A2—Estrone—prostate cancer	0.027	0.0527	CbGbCtD
Maprotiline—ABCB1—Cabazitaxel—prostate cancer	0.0241	0.0471	CbGbCtD
Maprotiline—ABCB1—Estrone—prostate cancer	0.0236	0.046	CbGbCtD
Maprotiline—ABCB1—Ethinyl Estradiol—prostate cancer	0.021	0.041	CbGbCtD
Maprotiline—CYP1A2—Conjugated Estrogens—prostate cancer	0.0176	0.0344	CbGbCtD
Maprotiline—HTR7—vas deferens—prostate cancer	0.0157	0.24	CbGeAlD
Maprotiline—CYP1A2—Estradiol—prostate cancer	0.0155	0.0302	CbGbCtD
Maprotiline—ABCB1—Conjugated Estrogens—prostate cancer	0.0154	0.0301	CbGbCtD
Maprotiline—ABCB1—Mitoxantrone—prostate cancer	0.014	0.0274	CbGbCtD
Maprotiline—ABCB1—Estradiol—prostate cancer	0.0135	0.0264	CbGbCtD
Maprotiline—CHRM3—ureter—prostate cancer	0.0126	0.193	CbGeAlD
Maprotiline—ABCB1—Prednisone—prostate cancer	0.0116	0.0227	CbGbCtD
Maprotiline—CYP1A2—Etoposide—prostate cancer	0.0101	0.0197	CbGbCtD
Maprotiline—ABCB1—Etoposide—prostate cancer	0.00884	0.0173	CbGbCtD
Maprotiline—ABCB1—Docetaxel—prostate cancer	0.00809	0.0158	CbGbCtD
Maprotiline—ABCB1—Doxorubicin—prostate cancer	0.00603	0.0118	CbGbCtD
Maprotiline—CYP2D6—Doxorubicin—prostate cancer	0.00568	0.0111	CbGbCtD
Maprotiline—CYP1A2—urine—prostate cancer	0.00312	0.0477	CbGeAlD
Maprotiline—HTR2A—urine—prostate cancer	0.00244	0.0373	CbGeAlD
Maprotiline—CYP2D6—urine—prostate cancer	0.00222	0.034	CbGeAlD
Maprotiline—ORM1—prostate gland—prostate cancer	0.00194	0.0297	CbGeAlD
Maprotiline—CHRM5—epithelium—prostate cancer	0.00194	0.0296	CbGeAlD
Maprotiline—CHRM2—prostate gland—prostate cancer	0.00181	0.0277	CbGeAlD
Maprotiline—CHRM1—prostate gland—prostate cancer	0.00165	0.0252	CbGeAlD
Maprotiline—CHRM4—testis—prostate cancer	0.00149	0.0227	CbGeAlD
Maprotiline—CHRM3—prostate gland—prostate cancer	0.00147	0.0226	CbGeAlD
Maprotiline—HRH1—prostate gland—prostate cancer	0.00105	0.016	CbGeAlD
Maprotiline—HTR7—epithelium—prostate cancer	0.00103	0.0158	CbGeAlD
Maprotiline—CHRM3—renal system—prostate cancer	0.001	0.0154	CbGeAlD
Maprotiline—ORM1—bone marrow—prostate cancer	0.001	0.0153	CbGeAlD
Maprotiline—Dimetacrine—ACHE—prostate cancer	0.000995	0.188	CrCbGaD
Maprotiline—CHRM3—urethra—prostate cancer	0.000987	0.0151	CbGeAlD
Maprotiline—HTR7—renal system—prostate cancer	0.000956	0.0146	CbGeAlD
Maprotiline—SLC6A3—testis—prostate cancer	0.000795	0.0122	CbGeAlD
Maprotiline—HRH1—epithelium—prostate cancer	0.00077	0.0118	CbGeAlD
Maprotiline—CYP1A2—renal system—prostate cancer	0.000763	0.0117	CbGeAlD
Maprotiline—HRH1—urethra—prostate cancer	0.000701	0.0107	CbGeAlD
Maprotiline—Sertraline—CYP2C19—prostate cancer	0.000658	0.125	CrCbGaD
Maprotiline—CHRM3—testis—prostate cancer	0.000649	0.00994	CbGeAlD
Maprotiline—HTR2A—epithelium—prostate cancer	0.000643	0.00984	CbGeAlD
Maprotiline—SLC6A2—testis—prostate cancer	0.000641	0.00981	CbGeAlD
Maprotiline—ORM1—lymph node—prostate cancer	0.00062	0.00948	CbGeAlD
Maprotiline—HTR7—testis—prostate cancer	0.000618	0.00946	CbGeAlD
Maprotiline—HTR2A—renal system—prostate cancer	0.000596	0.00913	CbGeAlD
Maprotiline—DRD2—testis—prostate cancer	0.000584	0.00894	CbGeAlD
Maprotiline—ABCB1—prostate gland—prostate cancer	0.000573	0.00877	CbGeAlD
Maprotiline—CYP2D6—renal system—prostate cancer	0.000543	0.00831	CbGeAlD
Maprotiline—ABCB1—seminal vesicle—prostate cancer	0.000485	0.00742	CbGeAlD
Maprotiline—SLC6A2—lymph node—prostate cancer	0.000465	0.00711	CbGeAlD
Maprotiline—HRH1—testis—prostate cancer	0.000461	0.00706	CbGeAlD
Maprotiline—ABCB1—epithelium—prostate cancer	0.000421	0.00645	CbGeAlD
Maprotiline—Sertraline—CYP3A4—prostate cancer	0.000419	0.0792	CrCbGaD
Maprotiline—ABCB1—renal system—prostate cancer	0.000391	0.00598	CbGeAlD
Maprotiline—HTR2A—testis—prostate cancer	0.000385	0.0059	CbGeAlD
Maprotiline—ABCB1—urethra—prostate cancer	0.000384	0.00587	CbGeAlD
Maprotiline—CYP2D6—testis—prostate cancer	0.000351	0.00537	CbGeAlD
Maprotiline—HRH1—lymph node—prostate cancer	0.000334	0.00512	CbGeAlD
Maprotiline—Desipramine—SLC22A3—prostate cancer	0.000303	0.0573	CrCbGaD
Maprotiline—ABCB1—bone marrow—prostate cancer	0.000295	0.00452	CbGeAlD
Maprotiline—Desipramine—CYP2C18—prostate cancer	0.000266	0.0504	CrCbGaD
Maprotiline—Imipramine—SLC22A3—prostate cancer	0.000257	0.0486	CrCbGaD
Maprotiline—ABCB1—testis—prostate cancer	0.000253	0.00386	CbGeAlD
Maprotiline—Imipramine—CYP2C18—prostate cancer	0.000226	0.0427	CrCbGaD
Maprotiline—Desipramine—SLC22A1—prostate cancer	0.000217	0.0411	CrCbGaD
Maprotiline—Nortriptyline—CYP3A5—prostate cancer	0.000213	0.0403	CrCbGaD
Maprotiline—Imipramine—SLC22A1—prostate cancer	0.000184	0.0349	CrCbGaD
Maprotiline—ABCB1—lymph node—prostate cancer	0.000183	0.0028	CbGeAlD
Maprotiline—Desipramine—CYP2A6—prostate cancer	0.00017	0.0321	CrCbGaD
Maprotiline—Atomoxetine—CYP2C19—prostate cancer	0.000166	0.0314	CrCbGaD
Maprotiline—Nortriptyline—CYP2E1—prostate cancer	0.000146	0.0277	CrCbGaD
Maprotiline—Nortriptyline—CYP2C19—prostate cancer	0.000145	0.0274	CrCbGaD
Maprotiline—Desipramine—ADRB2—prostate cancer	0.000139	0.0262	CrCbGaD
Maprotiline—Desipramine—CYP2E1—prostate cancer	0.00012	0.0228	CrCbGaD
Maprotiline—Desipramine—CYP2C19—prostate cancer	0.000119	0.0226	CrCbGaD
Maprotiline—Atomoxetine—CYP3A4—prostate cancer	0.000105	0.02	CrCbGaD
Maprotiline—Imipramine—CYP2E1—prostate cancer	0.000102	0.0193	CrCbGaD
Maprotiline—Imipramine—CYP2C19—prostate cancer	0.000101	0.0191	CrCbGaD
Maprotiline—Nortriptyline—CYP3A4—prostate cancer	9.21e-05	0.0174	CrCbGaD
Maprotiline—Photosensitivity reaction—Doxorubicin—prostate cancer	8.27e-05	0.000299	CcSEcCtD
Maprotiline—Hepatobiliary disease—Epirubicin—prostate cancer	8.26e-05	0.000299	CcSEcCtD
Maprotiline—Oedema—Docetaxel—prostate cancer	8.26e-05	0.000299	CcSEcCtD
Maprotiline—Weight increased—Doxorubicin—prostate cancer	8.25e-05	0.000299	CcSEcCtD
Maprotiline—Vision blurred—Prednisone—prostate cancer	8.23e-05	0.000298	CcSEcCtD
Maprotiline—Infection—Docetaxel—prostate cancer	8.21e-05	0.000297	CcSEcCtD
Maprotiline—Weight decreased—Doxorubicin—prostate cancer	8.2e-05	0.000297	CcSEcCtD
Maprotiline—Feeling abnormal—Etoposide—prostate cancer	8.19e-05	0.000296	CcSEcCtD
Maprotiline—Diarrhoea—Mitoxantrone—prostate cancer	8.18e-05	0.000296	CcSEcCtD
Maprotiline—Dry mouth—Capecitabine—prostate cancer	8.16e-05	0.000295	CcSEcCtD
Maprotiline—Vomiting—Estradiol—prostate cancer	8.15e-05	0.000295	CcSEcCtD
Maprotiline—Agranulocytosis—Epirubicin—prostate cancer	8.15e-05	0.000295	CcSEcCtD
Maprotiline—Gastrointestinal pain—Etoposide—prostate cancer	8.13e-05	0.000294	CcSEcCtD
Maprotiline—Shock—Docetaxel—prostate cancer	8.13e-05	0.000294	CcSEcCtD
Maprotiline—Nervous system disorder—Docetaxel—prostate cancer	8.1e-05	0.000293	CcSEcCtD
Maprotiline—Thrombocytopenia—Docetaxel—prostate cancer	8.09e-05	0.000293	CcSEcCtD
Maprotiline—Rash—Estradiol—prostate cancer	8.09e-05	0.000293	CcSEcCtD
Maprotiline—Infestation NOS—Doxorubicin—prostate cancer	8.08e-05	0.000292	CcSEcCtD
Maprotiline—Drowsiness—Doxorubicin—prostate cancer	8.08e-05	0.000292	CcSEcCtD
Maprotiline—Infestation—Doxorubicin—prostate cancer	8.08e-05	0.000292	CcSEcCtD
Maprotiline—Dermatitis—Estradiol—prostate cancer	8.08e-05	0.000292	CcSEcCtD
Maprotiline—Confusional state—Capecitabine—prostate cancer	8.06e-05	0.000292	CcSEcCtD
Maprotiline—Tachycardia—Docetaxel—prostate cancer	8.06e-05	0.000292	CcSEcCtD
Maprotiline—Headache—Estradiol—prostate cancer	8.03e-05	0.000291	CcSEcCtD
Maprotiline—Skin disorder—Docetaxel—prostate cancer	8.02e-05	0.00029	CcSEcCtD
Maprotiline—Agitation—Prednisone—prostate cancer	8.02e-05	0.00029	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	8.01e-05	0.00029	CcSEcCtD
Maprotiline—Oedema—Capecitabine—prostate cancer	8e-05	0.000289	CcSEcCtD
Maprotiline—Infection—Capecitabine—prostate cancer	7.94e-05	0.000287	CcSEcCtD
Maprotiline—Neuropathy peripheral—Doxorubicin—prostate cancer	7.92e-05	0.000287	CcSEcCtD
Maprotiline—Urticaria—Etoposide—prostate cancer	7.9e-05	0.000286	CcSEcCtD
Maprotiline—Jaundice—Doxorubicin—prostate cancer	7.88e-05	0.000285	CcSEcCtD
Maprotiline—Stomatitis—Doxorubicin—prostate cancer	7.88e-05	0.000285	CcSEcCtD
Maprotiline—Shock—Capecitabine—prostate cancer	7.87e-05	0.000285	CcSEcCtD
Maprotiline—Abdominal pain—Etoposide—prostate cancer	7.86e-05	0.000284	CcSEcCtD
Maprotiline—Body temperature increased—Etoposide—prostate cancer	7.86e-05	0.000284	CcSEcCtD
Maprotiline—Nervous system disorder—Capecitabine—prostate cancer	7.84e-05	0.000284	CcSEcCtD
Maprotiline—Hepatitis—Epirubicin—prostate cancer	7.84e-05	0.000284	CcSEcCtD
Maprotiline—Thrombocytopenia—Capecitabine—prostate cancer	7.83e-05	0.000283	CcSEcCtD
Maprotiline—Syncope—Prednisone—prostate cancer	7.83e-05	0.000283	CcSEcCtD
Maprotiline—Tachycardia—Capecitabine—prostate cancer	7.81e-05	0.000282	CcSEcCtD
Maprotiline—Hypoaesthesia—Epirubicin—prostate cancer	7.8e-05	0.000282	CcSEcCtD
Maprotiline—Skin disorder—Capecitabine—prostate cancer	7.77e-05	0.000281	CcSEcCtD
Maprotiline—Urinary tract disorder—Epirubicin—prostate cancer	7.74e-05	0.00028	CcSEcCtD
Maprotiline—Hyperhidrosis—Capecitabine—prostate cancer	7.73e-05	0.00028	CcSEcCtD
Maprotiline—Hypotension—Docetaxel—prostate cancer	7.72e-05	0.000279	CcSEcCtD
Maprotiline—Urethral disorder—Epirubicin—prostate cancer	7.69e-05	0.000278	CcSEcCtD
Maprotiline—Loss of consciousness—Prednisone—prostate cancer	7.67e-05	0.000278	CcSEcCtD
Maprotiline—Hepatobiliary disease—Doxorubicin—prostate cancer	7.64e-05	0.000277	CcSEcCtD
Maprotiline—Nausea—Estradiol—prostate cancer	7.62e-05	0.000276	CcSEcCtD
Maprotiline—Vomiting—Mitoxantrone—prostate cancer	7.6e-05	0.000275	CcSEcCtD
Maprotiline—Desipramine—CYP3A4—prostate cancer	7.58e-05	0.0144	CrCbGaD
Maprotiline—Convulsion—Prednisone—prostate cancer	7.56e-05	0.000274	CcSEcCtD
Maprotiline—Agranulocytosis—Doxorubicin—prostate cancer	7.54e-05	0.000273	CcSEcCtD
Maprotiline—Hypertension—Prednisone—prostate cancer	7.54e-05	0.000273	CcSEcCtD
Maprotiline—Rash—Mitoxantrone—prostate cancer	7.53e-05	0.000273	CcSEcCtD
Maprotiline—Dermatitis—Mitoxantrone—prostate cancer	7.53e-05	0.000272	CcSEcCtD
Maprotiline—Headache—Mitoxantrone—prostate cancer	7.49e-05	0.000271	CcSEcCtD
Maprotiline—Hypotension—Capecitabine—prostate cancer	7.47e-05	0.00027	CcSEcCtD
Maprotiline—Insomnia—Docetaxel—prostate cancer	7.47e-05	0.00027	CcSEcCtD
Maprotiline—Paraesthesia—Docetaxel—prostate cancer	7.42e-05	0.000268	CcSEcCtD
Maprotiline—Erythema multiforme—Epirubicin—prostate cancer	7.41e-05	0.000268	CcSEcCtD
Maprotiline—Anxiety—Prednisone—prostate cancer	7.41e-05	0.000268	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	7.38e-05	0.000267	CcSEcCtD
Maprotiline—Somnolence—Docetaxel—prostate cancer	7.34e-05	0.000266	CcSEcCtD
Maprotiline—Eye disorder—Epirubicin—prostate cancer	7.33e-05	0.000265	CcSEcCtD
Maprotiline—Tinnitus—Epirubicin—prostate cancer	7.31e-05	0.000265	CcSEcCtD
Maprotiline—Cardiac disorder—Epirubicin—prostate cancer	7.28e-05	0.000263	CcSEcCtD
Maprotiline—Flushing—Epirubicin—prostate cancer	7.28e-05	0.000263	CcSEcCtD
Maprotiline—Dyspepsia—Docetaxel—prostate cancer	7.27e-05	0.000263	CcSEcCtD
Maprotiline—Hepatitis—Doxorubicin—prostate cancer	7.26e-05	0.000263	CcSEcCtD
Maprotiline—Insomnia—Capecitabine—prostate cancer	7.23e-05	0.000262	CcSEcCtD
Maprotiline—Hypoaesthesia—Doxorubicin—prostate cancer	7.22e-05	0.000261	CcSEcCtD
Maprotiline—Paraesthesia—Capecitabine—prostate cancer	7.18e-05	0.00026	CcSEcCtD
Maprotiline—Urinary tract disorder—Doxorubicin—prostate cancer	7.17e-05	0.000259	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Docetaxel—prostate cancer	7.13e-05	0.000258	CcSEcCtD
Maprotiline—Asthenia—Etoposide—prostate cancer	7.13e-05	0.000258	CcSEcCtD
Maprotiline—Oedema—Prednisone—prostate cancer	7.12e-05	0.000258	CcSEcCtD
Maprotiline—Fatigue—Docetaxel—prostate cancer	7.12e-05	0.000258	CcSEcCtD
Maprotiline—Angiopathy—Epirubicin—prostate cancer	7.11e-05	0.000257	CcSEcCtD
Maprotiline—Urethral disorder—Doxorubicin—prostate cancer	7.11e-05	0.000257	CcSEcCtD
Maprotiline—Nausea—Mitoxantrone—prostate cancer	7.1e-05	0.000257	CcSEcCtD
Maprotiline—Infection—Prednisone—prostate cancer	7.08e-05	0.000256	CcSEcCtD
Maprotiline—Mediastinal disorder—Epirubicin—prostate cancer	7.07e-05	0.000256	CcSEcCtD
Maprotiline—Constipation—Docetaxel—prostate cancer	7.06e-05	0.000256	CcSEcCtD
Maprotiline—Dyspepsia—Capecitabine—prostate cancer	7.04e-05	0.000255	CcSEcCtD
Maprotiline—Pruritus—Etoposide—prostate cancer	7.03e-05	0.000254	CcSEcCtD
Maprotiline—Shock—Prednisone—prostate cancer	7.01e-05	0.000254	CcSEcCtD
Maprotiline—Arrhythmia—Epirubicin—prostate cancer	7.01e-05	0.000253	CcSEcCtD
Maprotiline—Nervous system disorder—Prednisone—prostate cancer	6.99e-05	0.000253	CcSEcCtD
Maprotiline—Tachycardia—Prednisone—prostate cancer	6.95e-05	0.000252	CcSEcCtD
Maprotiline—Alopecia—Epirubicin—prostate cancer	6.93e-05	0.000251	CcSEcCtD
Maprotiline—Skin disorder—Prednisone—prostate cancer	6.92e-05	0.00025	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Capecitabine—prostate cancer	6.9e-05	0.00025	CcSEcCtD
Maprotiline—Fatigue—Capecitabine—prostate cancer	6.89e-05	0.000249	CcSEcCtD
Maprotiline—Hyperhidrosis—Prednisone—prostate cancer	6.89e-05	0.000249	CcSEcCtD
Maprotiline—Erythema multiforme—Doxorubicin—prostate cancer	6.86e-05	0.000248	CcSEcCtD
Maprotiline—Constipation—Capecitabine—prostate cancer	6.84e-05	0.000247	CcSEcCtD
Maprotiline—Malnutrition—Epirubicin—prostate cancer	6.83e-05	0.000247	CcSEcCtD
Maprotiline—Feeling abnormal—Docetaxel—prostate cancer	6.81e-05	0.000246	CcSEcCtD
Maprotiline—Diarrhoea—Etoposide—prostate cancer	6.8e-05	0.000246	CcSEcCtD
Maprotiline—Eye disorder—Doxorubicin—prostate cancer	6.78e-05	0.000245	CcSEcCtD
Maprotiline—Tinnitus—Doxorubicin—prostate cancer	6.77e-05	0.000245	CcSEcCtD
Maprotiline—Gastrointestinal pain—Docetaxel—prostate cancer	6.75e-05	0.000244	CcSEcCtD
Maprotiline—Cardiac disorder—Doxorubicin—prostate cancer	6.73e-05	0.000244	CcSEcCtD
Maprotiline—Flushing—Doxorubicin—prostate cancer	6.73e-05	0.000244	CcSEcCtD
Maprotiline—Tension—Epirubicin—prostate cancer	6.7e-05	0.000242	CcSEcCtD
Maprotiline—Dysgeusia—Epirubicin—prostate cancer	6.68e-05	0.000242	CcSEcCtD
Maprotiline—Nervousness—Epirubicin—prostate cancer	6.63e-05	0.00024	CcSEcCtD
Maprotiline—Feeling abnormal—Capecitabine—prostate cancer	6.59e-05	0.000238	CcSEcCtD
Maprotiline—Angiopathy—Doxorubicin—prostate cancer	6.58e-05	0.000238	CcSEcCtD
Maprotiline—Dizziness—Etoposide—prostate cancer	6.57e-05	0.000238	CcSEcCtD
Maprotiline—Gastrointestinal pain—Capecitabine—prostate cancer	6.54e-05	0.000237	CcSEcCtD
Maprotiline—Mediastinal disorder—Doxorubicin—prostate cancer	6.54e-05	0.000237	CcSEcCtD
Maprotiline—Abdominal pain—Docetaxel—prostate cancer	6.53e-05	0.000236	CcSEcCtD
Maprotiline—Body temperature increased—Docetaxel—prostate cancer	6.53e-05	0.000236	CcSEcCtD
Maprotiline—Arrhythmia—Doxorubicin—prostate cancer	6.48e-05	0.000235	CcSEcCtD
Maprotiline—Insomnia—Prednisone—prostate cancer	6.44e-05	0.000233	CcSEcCtD
Maprotiline—Vision blurred—Epirubicin—prostate cancer	6.43e-05	0.000233	CcSEcCtD
Maprotiline—Imipramine—CYP3A4—prostate cancer	6.43e-05	0.0122	CrCbGaD
Maprotiline—Alopecia—Doxorubicin—prostate cancer	6.41e-05	0.000232	CcSEcCtD
Maprotiline—Paraesthesia—Prednisone—prostate cancer	6.4e-05	0.000231	CcSEcCtD
Maprotiline—Urticaria—Capecitabine—prostate cancer	6.35e-05	0.00023	CcSEcCtD
Maprotiline—Abdominal pain—Capecitabine—prostate cancer	6.32e-05	0.000229	CcSEcCtD
Maprotiline—Body temperature increased—Capecitabine—prostate cancer	6.32e-05	0.000229	CcSEcCtD
Maprotiline—Vomiting—Etoposide—prostate cancer	6.32e-05	0.000229	CcSEcCtD
Maprotiline—Malnutrition—Doxorubicin—prostate cancer	6.32e-05	0.000229	CcSEcCtD
Maprotiline—Agitation—Epirubicin—prostate cancer	6.27e-05	0.000227	CcSEcCtD
Maprotiline—Dyspepsia—Prednisone—prostate cancer	6.27e-05	0.000227	CcSEcCtD
Maprotiline—Rash—Etoposide—prostate cancer	6.27e-05	0.000227	CcSEcCtD
Maprotiline—Dermatitis—Etoposide—prostate cancer	6.26e-05	0.000227	CcSEcCtD
Maprotiline—Headache—Etoposide—prostate cancer	6.23e-05	0.000225	CcSEcCtD
Maprotiline—Tension—Doxorubicin—prostate cancer	6.2e-05	0.000224	CcSEcCtD
Maprotiline—Dysgeusia—Doxorubicin—prostate cancer	6.19e-05	0.000224	CcSEcCtD
Maprotiline—Fatigue—Prednisone—prostate cancer	6.14e-05	0.000222	CcSEcCtD
Maprotiline—Nervousness—Doxorubicin—prostate cancer	6.13e-05	0.000222	CcSEcCtD
Maprotiline—Syncope—Epirubicin—prostate cancer	6.12e-05	0.000222	CcSEcCtD
Maprotiline—Leukopenia—Epirubicin—prostate cancer	6.11e-05	0.000221	CcSEcCtD
Maprotiline—Constipation—Prednisone—prostate cancer	6.09e-05	0.00022	CcSEcCtD
Maprotiline—Palpitations—Epirubicin—prostate cancer	6.03e-05	0.000218	CcSEcCtD
Maprotiline—Loss of consciousness—Epirubicin—prostate cancer	6e-05	0.000217	CcSEcCtD
Maprotiline—Vision blurred—Doxorubicin—prostate cancer	5.95e-05	0.000215	CcSEcCtD
Maprotiline—Asthenia—Docetaxel—prostate cancer	5.93e-05	0.000214	CcSEcCtD
Maprotiline—Convulsion—Epirubicin—prostate cancer	5.91e-05	0.000214	CcSEcCtD
Maprotiline—Nausea—Etoposide—prostate cancer	5.9e-05	0.000214	CcSEcCtD
Maprotiline—Hypertension—Epirubicin—prostate cancer	5.89e-05	0.000213	CcSEcCtD
Maprotiline—Feeling abnormal—Prednisone—prostate cancer	5.87e-05	0.000212	CcSEcCtD
Maprotiline—Pruritus—Docetaxel—prostate cancer	5.84e-05	0.000211	CcSEcCtD
Maprotiline—Gastrointestinal pain—Prednisone—prostate cancer	5.82e-05	0.000211	CcSEcCtD
Maprotiline—Agitation—Doxorubicin—prostate cancer	5.8e-05	0.00021	CcSEcCtD
Maprotiline—Anxiety—Epirubicin—prostate cancer	5.79e-05	0.00021	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.77e-05	0.000209	CcSEcCtD
Maprotiline—Asthenia—Capecitabine—prostate cancer	5.74e-05	0.000208	CcSEcCtD
Maprotiline—Dry mouth—Epirubicin—prostate cancer	5.68e-05	0.000206	CcSEcCtD
Maprotiline—Syncope—Doxorubicin—prostate cancer	5.66e-05	0.000205	CcSEcCtD
Maprotiline—Urticaria—Prednisone—prostate cancer	5.66e-05	0.000205	CcSEcCtD
Maprotiline—Pruritus—Capecitabine—prostate cancer	5.66e-05	0.000205	CcSEcCtD
Maprotiline—Leukopenia—Doxorubicin—prostate cancer	5.65e-05	0.000205	CcSEcCtD
Maprotiline—Diarrhoea—Docetaxel—prostate cancer	5.65e-05	0.000205	CcSEcCtD
Maprotiline—Body temperature increased—Prednisone—prostate cancer	5.63e-05	0.000204	CcSEcCtD
Maprotiline—Abdominal pain—Prednisone—prostate cancer	5.63e-05	0.000204	CcSEcCtD
Maprotiline—Confusional state—Epirubicin—prostate cancer	5.62e-05	0.000203	CcSEcCtD
Maprotiline—Palpitations—Doxorubicin—prostate cancer	5.58e-05	0.000202	CcSEcCtD
Maprotiline—Oedema—Epirubicin—prostate cancer	5.57e-05	0.000202	CcSEcCtD
Maprotiline—Loss of consciousness—Doxorubicin—prostate cancer	5.55e-05	0.000201	CcSEcCtD
Maprotiline—Infection—Epirubicin—prostate cancer	5.53e-05	0.0002	CcSEcCtD
Maprotiline—Shock—Epirubicin—prostate cancer	5.48e-05	0.000198	CcSEcCtD
Maprotiline—Convulsion—Doxorubicin—prostate cancer	5.47e-05	0.000198	CcSEcCtD
Maprotiline—Diarrhoea—Capecitabine—prostate cancer	5.47e-05	0.000198	CcSEcCtD
Maprotiline—Nervous system disorder—Epirubicin—prostate cancer	5.46e-05	0.000198	CcSEcCtD
Maprotiline—Dizziness—Docetaxel—prostate cancer	5.46e-05	0.000198	CcSEcCtD
Maprotiline—Thrombocytopenia—Epirubicin—prostate cancer	5.45e-05	0.000197	CcSEcCtD
Maprotiline—Hypertension—Doxorubicin—prostate cancer	5.45e-05	0.000197	CcSEcCtD
Maprotiline—Tachycardia—Epirubicin—prostate cancer	5.44e-05	0.000197	CcSEcCtD
Maprotiline—Skin disorder—Epirubicin—prostate cancer	5.41e-05	0.000196	CcSEcCtD
Maprotiline—Hyperhidrosis—Epirubicin—prostate cancer	5.39e-05	0.000195	CcSEcCtD
Maprotiline—Anxiety—Doxorubicin—prostate cancer	5.36e-05	0.000194	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.34e-05	0.000193	CcSEcCtD
Maprotiline—Dizziness—Capecitabine—prostate cancer	5.29e-05	0.000191	CcSEcCtD
Maprotiline—Dry mouth—Doxorubicin—prostate cancer	5.26e-05	0.00019	CcSEcCtD
Maprotiline—Vomiting—Docetaxel—prostate cancer	5.25e-05	0.00019	CcSEcCtD
Maprotiline—Rash—Docetaxel—prostate cancer	5.21e-05	0.000188	CcSEcCtD
Maprotiline—Hypotension—Epirubicin—prostate cancer	5.21e-05	0.000188	CcSEcCtD
Maprotiline—Dermatitis—Docetaxel—prostate cancer	5.2e-05	0.000188	CcSEcCtD
Maprotiline—Confusional state—Doxorubicin—prostate cancer	5.2e-05	0.000188	CcSEcCtD
Maprotiline—Headache—Docetaxel—prostate cancer	5.17e-05	0.000187	CcSEcCtD
Maprotiline—Oedema—Doxorubicin—prostate cancer	5.15e-05	0.000187	CcSEcCtD
Maprotiline—Infection—Doxorubicin—prostate cancer	5.12e-05	0.000185	CcSEcCtD
Maprotiline—Asthenia—Prednisone—prostate cancer	5.11e-05	0.000185	CcSEcCtD
Maprotiline—Vomiting—Capecitabine—prostate cancer	5.08e-05	0.000184	CcSEcCtD
Maprotiline—Shock—Doxorubicin—prostate cancer	5.07e-05	0.000184	CcSEcCtD
Maprotiline—Nervous system disorder—Doxorubicin—prostate cancer	5.06e-05	0.000183	CcSEcCtD
Maprotiline—Thrombocytopenia—Doxorubicin—prostate cancer	5.05e-05	0.000183	CcSEcCtD
Maprotiline—Rash—Capecitabine—prostate cancer	5.04e-05	0.000182	CcSEcCtD
Maprotiline—Pruritus—Prednisone—prostate cancer	5.04e-05	0.000182	CcSEcCtD
Maprotiline—Insomnia—Epirubicin—prostate cancer	5.04e-05	0.000182	CcSEcCtD
Maprotiline—Dermatitis—Capecitabine—prostate cancer	5.04e-05	0.000182	CcSEcCtD
Maprotiline—Tachycardia—Doxorubicin—prostate cancer	5.03e-05	0.000182	CcSEcCtD
Maprotiline—Headache—Capecitabine—prostate cancer	5.01e-05	0.000181	CcSEcCtD
Maprotiline—Skin disorder—Doxorubicin—prostate cancer	5.01e-05	0.000181	CcSEcCtD
Maprotiline—Paraesthesia—Epirubicin—prostate cancer	5e-05	0.000181	CcSEcCtD
Maprotiline—Hyperhidrosis—Doxorubicin—prostate cancer	4.98e-05	0.00018	CcSEcCtD
Maprotiline—Somnolence—Epirubicin—prostate cancer	4.95e-05	0.000179	CcSEcCtD
Maprotiline—Nausea—Docetaxel—prostate cancer	4.91e-05	0.000178	CcSEcCtD
Maprotiline—Dyspepsia—Epirubicin—prostate cancer	4.9e-05	0.000177	CcSEcCtD
Maprotiline—Diarrhoea—Prednisone—prostate cancer	4.87e-05	0.000176	CcSEcCtD
Maprotiline—Hypotension—Doxorubicin—prostate cancer	4.82e-05	0.000174	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Epirubicin—prostate cancer	4.81e-05	0.000174	CcSEcCtD
Maprotiline—Fatigue—Epirubicin—prostate cancer	4.8e-05	0.000174	CcSEcCtD
Maprotiline—Constipation—Epirubicin—prostate cancer	4.76e-05	0.000172	CcSEcCtD
Maprotiline—Nausea—Capecitabine—prostate cancer	4.75e-05	0.000172	CcSEcCtD
Maprotiline—Dizziness—Prednisone—prostate cancer	4.71e-05	0.00017	CcSEcCtD
Maprotiline—Insomnia—Doxorubicin—prostate cancer	4.66e-05	0.000169	CcSEcCtD
Maprotiline—Paraesthesia—Doxorubicin—prostate cancer	4.63e-05	0.000168	CcSEcCtD
Maprotiline—Feeling abnormal—Epirubicin—prostate cancer	4.59e-05	0.000166	CcSEcCtD
Maprotiline—Somnolence—Doxorubicin—prostate cancer	4.58e-05	0.000166	CcSEcCtD
Maprotiline—Gastrointestinal pain—Epirubicin—prostate cancer	4.56e-05	0.000165	CcSEcCtD
Maprotiline—Dyspepsia—Doxorubicin—prostate cancer	4.54e-05	0.000164	CcSEcCtD
Maprotiline—Vomiting—Prednisone—prostate cancer	4.53e-05	0.000164	CcSEcCtD
Maprotiline—Rash—Prednisone—prostate cancer	4.49e-05	0.000163	CcSEcCtD
Maprotiline—Dermatitis—Prednisone—prostate cancer	4.49e-05	0.000162	CcSEcCtD
Maprotiline—Headache—Prednisone—prostate cancer	4.46e-05	0.000161	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.45e-05	0.000161	CcSEcCtD
Maprotiline—Fatigue—Doxorubicin—prostate cancer	4.44e-05	0.000161	CcSEcCtD
Maprotiline—Urticaria—Epirubicin—prostate cancer	4.43e-05	0.00016	CcSEcCtD
Maprotiline—Constipation—Doxorubicin—prostate cancer	4.41e-05	0.00016	CcSEcCtD
Maprotiline—Abdominal pain—Epirubicin—prostate cancer	4.4e-05	0.000159	CcSEcCtD
Maprotiline—Body temperature increased—Epirubicin—prostate cancer	4.4e-05	0.000159	CcSEcCtD
Maprotiline—Feeling abnormal—Doxorubicin—prostate cancer	4.25e-05	0.000154	CcSEcCtD
Maprotiline—Nausea—Prednisone—prostate cancer	4.23e-05	0.000153	CcSEcCtD
Maprotiline—Gastrointestinal pain—Doxorubicin—prostate cancer	4.22e-05	0.000153	CcSEcCtD
Maprotiline—Urticaria—Doxorubicin—prostate cancer	4.1e-05	0.000148	CcSEcCtD
Maprotiline—Abdominal pain—Doxorubicin—prostate cancer	4.08e-05	0.000147	CcSEcCtD
Maprotiline—Body temperature increased—Doxorubicin—prostate cancer	4.08e-05	0.000147	CcSEcCtD
Maprotiline—Asthenia—Epirubicin—prostate cancer	4e-05	0.000145	CcSEcCtD
Maprotiline—Pruritus—Epirubicin—prostate cancer	3.94e-05	0.000143	CcSEcCtD
Maprotiline—Diarrhoea—Epirubicin—prostate cancer	3.81e-05	0.000138	CcSEcCtD
Maprotiline—Asthenia—Doxorubicin—prostate cancer	3.7e-05	0.000134	CcSEcCtD
Maprotiline—Dizziness—Epirubicin—prostate cancer	3.68e-05	0.000133	CcSEcCtD
Maprotiline—Pruritus—Doxorubicin—prostate cancer	3.65e-05	0.000132	CcSEcCtD
Maprotiline—Vomiting—Epirubicin—prostate cancer	3.54e-05	0.000128	CcSEcCtD
Maprotiline—Diarrhoea—Doxorubicin—prostate cancer	3.53e-05	0.000128	CcSEcCtD
Maprotiline—Rash—Epirubicin—prostate cancer	3.51e-05	0.000127	CcSEcCtD
Maprotiline—Dermatitis—Epirubicin—prostate cancer	3.51e-05	0.000127	CcSEcCtD
Maprotiline—Headache—Epirubicin—prostate cancer	3.49e-05	0.000126	CcSEcCtD
Maprotiline—Dizziness—Doxorubicin—prostate cancer	3.41e-05	0.000123	CcSEcCtD
Maprotiline—Nausea—Epirubicin—prostate cancer	3.31e-05	0.00012	CcSEcCtD
Maprotiline—Vomiting—Doxorubicin—prostate cancer	3.28e-05	0.000119	CcSEcCtD
Maprotiline—Rash—Doxorubicin—prostate cancer	3.25e-05	0.000118	CcSEcCtD
Maprotiline—Dermatitis—Doxorubicin—prostate cancer	3.25e-05	0.000118	CcSEcCtD
Maprotiline—Headache—Doxorubicin—prostate cancer	3.23e-05	0.000117	CcSEcCtD
Maprotiline—Nausea—Doxorubicin—prostate cancer	3.06e-05	0.000111	CcSEcCtD
Maprotiline—CHRM3—Signaling Pathways—JAK2—prostate cancer	3.12e-06	2.21e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—KRAS—prostate cancer	3.1e-06	2.2e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—LPL—prostate cancer	3.1e-06	2.2e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—EGFR—prostate cancer	3.1e-06	2.2e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—JAK2—prostate cancer	3.09e-06	2.19e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	3.09e-06	2.19e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CCND1—prostate cancer	3.08e-06	2.19e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—ERBB2—prostate cancer	3.08e-06	2.18e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—PIK3CA—prostate cancer	3.08e-06	2.18e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MDM2—prostate cancer	3.07e-06	2.18e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	3.07e-06	2.18e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MDM2—prostate cancer	3.07e-06	2.17e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTEN—prostate cancer	3.06e-06	2.17e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—PIK3CA—prostate cancer	3.06e-06	2.17e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MDM2—prostate cancer	3.06e-06	2.17e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CTNNB1—prostate cancer	3.05e-06	2.16e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MDM2—prostate cancer	3.05e-06	2.16e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CB—prostate cancer	3.04e-06	2.16e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CAV1—prostate cancer	3.04e-06	2.15e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MYC—prostate cancer	3.03e-06	2.15e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—ERBB2—prostate cancer	3.03e-06	2.15e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	3.03e-06	2.15e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TGFB1—prostate cancer	3.03e-06	2.15e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—ERBB2—prostate cancer	3.02e-06	2.14e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MDM2—prostate cancer	3.02e-06	2.14e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—ERBB2—prostate cancer	3.01e-06	2.14e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—ERBB2—prostate cancer	3.01e-06	2.13e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MMP9—prostate cancer	2.99e-06	2.12e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CYP1A1—prostate cancer	2.99e-06	2.12e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	2.99e-06	2.12e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CB—prostate cancer	2.98e-06	2.12e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	2.98e-06	2.11e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PTEN—prostate cancer	2.98e-06	2.11e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—ERBB2—prostate cancer	2.98e-06	2.11e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	2.97e-06	2.11e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ERCC2—prostate cancer	2.97e-06	2.1e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—EGFR—prostate cancer	2.97e-06	2.1e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CB—prostate cancer	2.97e-06	2.1e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CG—prostate cancer	2.94e-06	2.08e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	2.94e-06	2.08e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—KRAS—prostate cancer	2.93e-06	2.08e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—EP300—prostate cancer	2.92e-06	2.07e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CXCL8—prostate cancer	2.92e-06	2.07e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—AKT1—prostate cancer	2.9e-06	2.06e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CXCL8—prostate cancer	2.87e-06	2.04e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CXCL8—prostate cancer	2.87e-06	2.03e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CXCL8—prostate cancer	2.86e-06	2.03e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CDKN1B—prostate cancer	2.85e-06	2.02e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CXCL8—prostate cancer	2.85e-06	2.02e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—PIK3CA—prostate cancer	2.85e-06	2.02e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—EP300—prostate cancer	2.84e-06	2.01e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CXCL8—prostate cancer	2.82e-06	2e-05	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—AKT1—prostate cancer	2.82e-06	2e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	2.81e-06	1.99e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—KRAS—prostate cancer	2.8e-06	1.99e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CDKN1B—prostate cancer	2.8e-06	1.99e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CASP3—prostate cancer	2.8e-06	1.98e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	2.79e-06	1.98e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL2—prostate cancer	2.79e-06	1.98e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—MTHFR—prostate cancer	2.79e-06	1.98e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CDKN1B—prostate cancer	2.78e-06	1.97e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—INS—prostate cancer	2.78e-06	1.97e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—IL6—prostate cancer	2.78e-06	1.97e-05	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	2.78e-06	1.97e-05	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—AKT1—prostate cancer	2.77e-06	1.96e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.77e-06	1.96e-05	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	2.76e-06	1.96e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SRC—prostate cancer	2.76e-06	1.96e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	2.76e-06	1.95e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TP53—prostate cancer	2.76e-06	1.95e-05	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—AKT1—prostate cancer	2.75e-06	1.95e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CASP3—prostate cancer	2.75e-06	1.95e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL2—prostate cancer	2.75e-06	1.95e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CASP3—prostate cancer	2.75e-06	1.95e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL2—prostate cancer	2.74e-06	1.94e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPARA—prostate cancer	2.74e-06	1.94e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CASP3—prostate cancer	2.74e-06	1.94e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—IL6—prostate cancer	2.73e-06	1.94e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL2—prostate cancer	2.73e-06	1.94e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CASP3—prostate cancer	2.73e-06	1.93e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—IL6—prostate cancer	2.73e-06	1.93e-05	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	2.73e-06	1.93e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL2—prostate cancer	2.72e-06	1.93e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CREBBP—prostate cancer	2.72e-06	1.93e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CCND1—prostate cancer	2.72e-06	1.93e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—IL6—prostate cancer	2.72e-06	1.93e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—IL6—prostate cancer	2.71e-06	1.92e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CASP3—prostate cancer	2.7e-06	1.91e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL2—prostate cancer	2.7e-06	1.91e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CTNNB1—prostate cancer	2.7e-06	1.91e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—PIK3CA—prostate cancer	2.69e-06	1.91e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—VEGFA—prostate cancer	2.69e-06	1.91e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—IL6—prostate cancer	2.68e-06	1.9e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CCND1—prostate cancer	2.68e-06	1.9e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CCND1—prostate cancer	2.67e-06	1.89e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CCND1—prostate cancer	2.66e-06	1.89e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—STAT3—prostate cancer	2.66e-06	1.89e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CCND1—prostate cancer	2.65e-06	1.88e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	2.65e-06	1.88e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CTNNB1—prostate cancer	2.65e-06	1.88e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MMP9—prostate cancer	2.64e-06	1.87e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	2.64e-06	1.87e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CDKN1A—prostate cancer	2.63e-06	1.87e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CCND1—prostate cancer	2.63e-06	1.86e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	2.63e-06	1.86e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PTEN—prostate cancer	2.63e-06	1.86e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—INS—prostate cancer	2.62e-06	1.86e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	2.6e-06	1.85e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TP53—prostate cancer	2.6e-06	1.84e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MMP9—prostate cancer	2.6e-06	1.84e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MMP9—prostate cancer	2.59e-06	1.84e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	2.59e-06	1.84e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MMP9—prostate cancer	2.59e-06	1.83e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CDKN1A—prostate cancer	2.58e-06	1.83e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PTEN—prostate cancer	2.58e-06	1.83e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CD—prostate cancer	2.58e-06	1.83e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PTEN—prostate cancer	2.58e-06	1.83e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MMP9—prostate cancer	2.58e-06	1.83e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	2.58e-06	1.83e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PIK3CA—prostate cancer	2.58e-06	1.83e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CAV1—prostate cancer	2.57e-06	1.82e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PTEN—prostate cancer	2.57e-06	1.82e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	2.57e-06	1.82e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CREBBP—prostate cancer	2.57e-06	1.82e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—AKT1—prostate cancer	2.56e-06	1.82e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PTEN—prostate cancer	2.56e-06	1.82e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MMP9—prostate cancer	2.55e-06	1.81e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	2.54e-06	1.8e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PTEN—prostate cancer	2.54e-06	1.8e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—IL6—prostate cancer	2.52e-06	1.79e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—AKT1—prostate cancer	2.52e-06	1.79e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—AKT1—prostate cancer	2.52e-06	1.78e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—AKT1—prostate cancer	2.51e-06	1.78e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—EP300—prostate cancer	2.51e-06	1.78e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—AKT1—prostate cancer	2.5e-06	1.77e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TP53—prostate cancer	2.49e-06	1.77e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—AKT1—prostate cancer	2.48e-06	1.76e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MYC—prostate cancer	2.47e-06	1.75e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TGFB1—prostate cancer	2.47e-06	1.75e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—EP300—prostate cancer	2.46e-06	1.75e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—EP300—prostate cancer	2.46e-06	1.74e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.46e-06	1.74e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—EP300—prostate cancer	2.45e-06	1.74e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—EP300—prostate cancer	2.44e-06	1.73e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—NOS3—prostate cancer	2.44e-06	1.73e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SRC—prostate cancer	2.44e-06	1.73e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.43e-06	1.72e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—EP300—prostate cancer	2.42e-06	1.72e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—EGFR—prostate cancer	2.42e-06	1.72e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SRC—prostate cancer	2.4e-06	1.7e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SRC—prostate cancer	2.39e-06	1.7e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SRC—prostate cancer	2.38e-06	1.69e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—IL6—prostate cancer	2.38e-06	1.69e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SRC—prostate cancer	2.38e-06	1.68e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—VEGFA—prostate cancer	2.37e-06	1.68e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SRC—prostate cancer	2.35e-06	1.67e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—STAT3—prostate cancer	2.35e-06	1.67e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CG—prostate cancer	2.34e-06	1.66e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—VEGFA—prostate cancer	2.33e-06	1.66e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—VEGFA—prostate cancer	2.33e-06	1.65e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—AKT1—prostate cancer	2.33e-06	1.65e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—VEGFA—prostate cancer	2.32e-06	1.65e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—VEGFA—prostate cancer	2.31e-06	1.64e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—STAT3—prostate cancer	2.31e-06	1.64e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—STAT3—prostate cancer	2.31e-06	1.64e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—STAT3—prostate cancer	2.3e-06	1.63e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—NOS3—prostate cancer	2.3e-06	1.63e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—VEGFA—prostate cancer	2.29e-06	1.63e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—STAT3—prostate cancer	2.29e-06	1.62e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—KRAS—prostate cancer	2.29e-06	1.62e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—IL6—prostate cancer	2.28e-06	1.62e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—STAT3—prostate cancer	2.27e-06	1.61e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CB—prostate cancer	2.25e-06	1.6e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTGS2—prostate cancer	2.23e-06	1.58e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—INS—prostate cancer	2.22e-06	1.57e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—AKT1—prostate cancer	2.2e-06	1.56e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MYC—prostate cancer	2.18e-06	1.55e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TGFB1—prostate cancer	2.18e-06	1.54e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CREBBP—prostate cancer	2.17e-06	1.54e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PIK3CA—prostate cancer	2.16e-06	1.53e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MYC—prostate cancer	2.15e-06	1.52e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MYC—prostate cancer	2.14e-06	1.52e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TGFB1—prostate cancer	2.14e-06	1.52e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TGFB1—prostate cancer	2.14e-06	1.52e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MYC—prostate cancer	2.14e-06	1.51e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—EGFR—prostate cancer	2.14e-06	1.51e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TGFB1—prostate cancer	2.13e-06	1.51e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MYC—prostate cancer	2.13e-06	1.51e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TGFB1—prostate cancer	2.12e-06	1.51e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CB—prostate cancer	2.12e-06	1.5e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MYC—prostate cancer	2.11e-06	1.5e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—AKT1—prostate cancer	2.1e-06	1.49e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TGFB1—prostate cancer	2.1e-06	1.49e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTGS2—prostate cancer	2.1e-06	1.49e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—EGFR—prostate cancer	2.1e-06	1.49e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	2.1e-06	1.49e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—EGFR—prostate cancer	2.1e-06	1.49e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—EGFR—prostate cancer	2.09e-06	1.48e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—EGFR—prostate cancer	2.08e-06	1.48e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—EGFR—prostate cancer	2.06e-06	1.46e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CD—prostate cancer	2.06e-06	1.46e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TP53—prostate cancer	2.03e-06	1.44e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—KRAS—prostate cancer	2.02e-06	1.43e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—KRAS—prostate cancer	1.98e-06	1.41e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KRAS—prostate cancer	1.98e-06	1.4e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KRAS—prostate cancer	1.97e-06	1.4e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KRAS—prostate cancer	1.97e-06	1.4e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KRAS—prostate cancer	1.95e-06	1.38e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—NOS3—prostate cancer	1.95e-06	1.38e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTEN—prostate cancer	1.94e-06	1.38e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL6—prostate cancer	1.86e-06	1.32e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—EP300—prostate cancer	1.85e-06	1.31e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CA—prostate cancer	1.85e-06	1.31e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTEN—prostate cancer	1.83e-06	1.3e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	1.82e-06	1.29e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CA—prostate cancer	1.82e-06	1.29e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	1.81e-06	1.29e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	1.81e-06	1.28e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CB—prostate cancer	1.8e-06	1.27e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TP53—prostate cancer	1.79e-06	1.27e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	1.79e-06	1.27e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTGS2—prostate cancer	1.78e-06	1.26e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—AKT1—prostate cancer	1.77e-06	1.25e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TP53—prostate cancer	1.76e-06	1.25e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TP53—prostate cancer	1.76e-06	1.25e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TP53—prostate cancer	1.75e-06	1.24e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TP53—prostate cancer	1.75e-06	1.24e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—EP300—prostate cancer	1.75e-06	1.24e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TP53—prostate cancer	1.73e-06	1.23e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—AKT1—prostate cancer	1.72e-06	1.22e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL6—prostate cancer	1.64e-06	1.16e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL6—prostate cancer	1.61e-06	1.14e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL6—prostate cancer	1.61e-06	1.14e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL6—prostate cancer	1.61e-06	1.14e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL6—prostate cancer	1.6e-06	1.13e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL6—prostate cancer	1.59e-06	1.12e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTEN—prostate cancer	1.55e-06	1.1e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—AKT1—prostate cancer	1.51e-06	1.07e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—AKT1—prostate cancer	1.49e-06	1.06e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—AKT1—prostate cancer	1.49e-06	1.05e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—AKT1—prostate cancer	1.48e-06	1.05e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—EP300—prostate cancer	1.48e-06	1.05e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—AKT1—prostate cancer	1.48e-06	1.05e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—AKT1—prostate cancer	1.46e-06	1.04e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CA—prostate cancer	1.37e-06	9.73e-06	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.29e-06	9.16e-06	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—AKT1—prostate cancer	1.12e-06	7.95e-06	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.1e-06	7.76e-06	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—AKT1—prostate cancer	1.06e-06	7.49e-06	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—AKT1—prostate cancer	8.95e-07	6.34e-06	CbGpPWpGaD
